RenovoRx, Inc. Common Stock
RNXTRenovoRx, Inc. (RNXT) is a clinical-stage healthcare company specializing in the development of targeted, minimally invasive delivery systems for oncology and other medical applications. The company focuses on innovative catheters designed to deliver therapies directly to tumors or affected tissues, aiming to improve treatment efficacy and reduce systemic side effects.
Company News
RenovoRx, Inc. (Nasdaq: RNXT) has been recognized as the #10 most innovative medical device company by Fast Company for 2026. The company generated $1.1 million in RenovoCath sales during its first full year of commercialization in 2025, with growing adoption at major cancer centers. The Phase III TIGeR-PaC trial for intra-arterial gemcitabine is...
Ongoing Study is Investigating RenovoGem™ to treat Locally Advanced Pancreatic Cancer Ongoing Study is Investigating RenovoGem™ to treat Locally Advanced Pancreatic Cancer
New role highlights RenovoRx’s commitment to explore and execute on clinical and commercial business development opportunities with its therapeutic technology New role highlights RenovoRx’s commitment to explore and execute on clinical and commercial business development opportunities with its therapeutic technology
Shares of Longboard Pharmaceuticals, Inc. (NASDAQ: LBPH) rose sharply during Tuesday’s session after the company released topline data from the PACIFIC Phase 1b/2a study evaluating bexicaserin (LP352) for seizures associated with a broad range of Developmental and Epileptic Encephalopathies (DEEs). Longboard Pharmaceuticals shares jumped 199....
Shares of DouYu International Holdings Limited (NASDAQ: DOYU) rose sharply during Thursday’s session after announcing a share repurchase program. DouYu plans repurchase of up to $20 million of ordinary shares in the form of ADSS during period of up to twelve months commencing on Jan. 1, 2024. DouYu International shares jumped 14.2% to $0.8320 ...
